Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Inclusion

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9,761 result(s) found for: Inclusion. Displaying page 1 of 489.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-001411-12 Sponsor Protocol Number: CBYM338B2203E1 Start Date*: 2015-11-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Extension of the CBYM338B2203 phase IIb/III study to evaluate the long-term efficacy, safety and tolerability of intravenous BYM338 in patients with sporadic inclusion body myositis
    Medical condition: Sporadic Inclusion Body Myositis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10066407 Inclusion body myositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) DK (Completed) GB (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000705-23 Sponsor Protocol Number: CBYM338B2203 Start Date*: 2014-02-09
    Sponsor Name:Novartis Farma SpA
    Full Title: A randomized, double-blind, placebo-controlled, multicenter, parallel group, dose-finding, pivotal, phase IIb/III study to evaluate the efficacy, safety and tolerability of intravenous BYM338 at 52...
    Medical condition: Sporadic Inclusion Body Myositis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10066407 Inclusion body myositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) NL (Completed) DE (Completed) BE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-008208-42 Sponsor Protocol Number: 08/0168 Start Date*: 2009-06-26
    Sponsor Name:UCL - The Joint UCLH/UCL Comprehensive Biomedical Research Unit
    Full Title: A Randomised, Double-Blind Placebo-Controlled Pilot Study Assessing the Safety and Tolerability of Arimoclomol in Adult with Sporadic Inclusion Body Myositis
    Medical condition: The research project proposes to investigate Sporadic Inclusion Body Myositis (IBM). IBM is the commonest acquired disease of muscle affecting people aged 50 years and over. It is a progressive and...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066407 Inclusion body myositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002150-39 Sponsor Protocol Number: CCSJ148X2201 Start Date*: 2015-03-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo controlled, study to evaluate the efficacy and safety of CSJ148 compared to placebo to prevent human cytomegalovirus (HCMV) replication in stem cel...
    Medical condition: human cytomegalovirus (HCMV) in stem cell transplant patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10009703 CMV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021433-32 Sponsor Protocol Number: GCV2010 Start Date*: 2011-03-29
    Sponsor Name:INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE(IDIBELL)
    Full Title: Individualización de las dosis de Ganciclovir/Valganciclovir por predicción bayesiana en pacientes trasplantados de órgano sólido infectados por citomegalovirus
    Medical condition: Enfermedad por citomegalovirus en trasplante de órgano sólido
    Disease: Version SOC Term Classification Code Term Level
    13 10011836 Infección por citomegalovirus LLT
    13 10058854 Viremia por citomegalovirus PT
    13 10011827 Infecciones por citomegalovirus HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001970-28 Sponsor Protocol Number: CMV-001 Start Date*: 2012-11-20
    Sponsor Name:University of Birmingham
    Full Title: Does CMV reactivation cause functional impairment of CMV specific CD4+ T-cells? The potential for valaciclovir to prevent CMV-mediated adverse modulation of the immune system in patients with ANCA-...
    Medical condition: This study will investigate the modulation of the immune system by Cytomegalovirus (CMV) in ANCA-associated vasculitis. Specifically the study will investigate the potential for valaciclovir to ...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    15.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-002603-15 Sponsor Protocol Number: GANCMV-2011 Start Date*: 2011-11-21
    Sponsor Name:FUNDACION INVESTIGACION HOSPITAL CLINICO DE VALENCIA-INSTITUTO DE INVESTIGACION SANITARIA INCLIVA
    Full Title: Early treatment with ganciclovir of active infection by cytomegalovirus (CMV) in critically ill patients on mechanical ventilation with severe sepsis or septic shock
    Medical condition: Active infection with cytomegalovirus (CMV) in critically ill patients on mechanical ventilation with severe sepsis or septic shock
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002069-11 Sponsor Protocol Number: 1 Start Date*: 2008-09-10
    Sponsor Name:Medizinische Universität Wien, Univ. Klinik für Innere Medizin III, Abteilung für Gastroenterologie
    Full Title: PHARMACOKINETICS OF GANCICLOVIR DURING CONTINUOUS RENAL REPLACEMENT THERAPY
    Medical condition: Medical Intensive Care Unit Renal failure Renal Replacement Therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038435 Renal failure LLT
    9.1 10011827 Cytomegaloviral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004795-35 Sponsor Protocol Number: CMX001-301 Start Date*: 2014-06-02
    Sponsor Name:Chimerix, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection ...
    Medical condition: Cytomegalovirus (CMV) Infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002102-58 Sponsor Protocol Number: TJT2012 Start Date*: 2020-06-12
    Sponsor Name:CHU de Liège
    Full Title: Mesenchymal stromal cell therapy for severe COVID-19 infection
    Medical condition: Patients with severe COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002245-37 Sponsor Protocol Number: GV28418 Start Date*: 2013-01-16
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF MCMV5322A/MCMV3068A FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN HIGH-RISK KIDNEY ALLOGRAFT RECIPIENTS
    Medical condition: Transplant-associated cytomegalovirus (CMV) infection
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    15.0 10021881 - Infections and infestations 10058881 Cytomegalovirus viremia LLT
    15.0 10021881 - Infections and infestations 10047438 Viral infectious disorders HLGT
    15.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    15.0 10021881 - Infections and infestations 10011827 Cytomegaloviral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) BE (Completed) GB (Completed) ES (Completed) DE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005191-18 Sponsor Protocol Number: HAF78 Start Date*: 2015-11-19
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Sanofi Pasteur’s AVAXIM 80U Pediatric Vaccine Administered in Healthy Adolescents, Children and Toddlers in People’s Republic of China Followed by a Booster Dose 6 Mont...
    Medical condition: Hepatitis A
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-001928-34 Sponsor Protocol Number: HALT_Covid-19 Start Date*: 2020-05-28
    Sponsor Name:Capio S:t Görans Sjukhus
    Full Title: Inhalation of Ciclesonide for patients with Covid-19: A randomised open treatment study (HALT Covid-19).
    Medical condition: Covid-19 pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001536-98 Sponsor Protocol Number: PREPSARS Start Date*: 2020-04-18
    Sponsor Name:HOSPITAL UNIVERSITARI MÚTUA TERRASSA
    Full Title: Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection.
    Medical condition: COVID-19 infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004445-17 Sponsor Protocol Number: hCMV2013 Start Date*: 2014-03-05
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE
    Full Title: A PROSPECTIVE RANDOMIZED STUDY FOR PREDICTING HUMAN CYTOMEGALOVIRUS (hCMV) INFECTION ACCORDING TO BASELINE hCMV-SPECIFIC T-CELL RESPONSE IN KIDNEY TRANSPLANT PATIENTS
    Medical condition: cytomegalovirus infection in renal tranplant recipients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001449-34 Sponsor Protocol Number: CMV-INMUNOGUIA Start Date*: 2011-08-19
    Sponsor Name:FUNDACION INVESTIGACION HOSPITAL CLINICO DE VALENCIA-INSTITUTO DE INVESTIGACION SANITARIA INCLIVA
    Full Title: Phase II study, multicenter, prospective, open label, preemptive treatment of cytomegalovirus (CMV) infection driven by virologic monitoring and quantification of T CD8pp65/IE-1-IFNgamma+ lymphocyt...
    Medical condition: Cytomegalovirus infection in patients treated with hematopoietic allogenic transplant
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10011827 Cytomegaloviral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-002374-82 Sponsor Protocol Number: TAK-620-3001 Start Date*: 2022-11-21
    Sponsor Name:Takeda
    Full Title: A Phase 3, Open-Label, Single-Arm Study to Assess the Efficacy, Safety, and Pharmacokinetics of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Japanese Recipients of a Hematopoie...
    Medical condition: Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003300-39 Sponsor Protocol Number: FCO-CYT-2018-01 Start Date*: 2018-12-21
    Sponsor Name:Fundación para la Investigación Biomédica de Córdoba
    Full Title: Clinical trial of efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis in lung transplant recipients.
    Medical condition: Cytomegalovirus Infection in subjects who underwent lung transplantation.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    20.0 10022117 - Injury, poisoning and procedural complications 10010187 Complications of transplanted lung PT
    20.0 10042613 - Surgical and medical procedures 10025127 Lung transplant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015965-29 Sponsor Protocol Number: ML 22371 Start Date*: 2010-05-17
    Sponsor Name:Pierrel Research Europe GmbH
    Full Title: Multicenter, randomized study comparing oral valganciclovir versus intravenous ganciclovir in patients following allogeneic stem cell transplantation
    Medical condition: Patients with a first episode of positive CMV-PCR (DNAemia) or pp65 antigenemia assay (antigenemia) up to 100 days after allogeneic SCT.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011831 Cytomegalovirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000837-17 Sponsor Protocol Number: NL80854.018.22 Start Date*: 2022-12-07
    Sponsor Name:Amsterdam UMC
    Full Title: Subcutaneous vedolizumab drug de-escalation using therapeutic drug monitoring in inflammatory bowel disease: a randomized controlled pilot study
    Medical condition: Inflammatory bowel diseases (Crohn's disease, ulcerative colitis)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 06 08:16:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA